Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Nasopharyngeal Carcinoma 2Urinary Bladder Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Pancreatic Cancer Metastatic 1Nasopharyngeal Neoplasms 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Breast Neoplasms 1Biliary Tract Neoplasms 1Advanced Renal Cell Carcinoma (RCC) 1Advanced Malignant Solid Tumors 1Advanced Lung Cancer 1Advanced Breast Cancer 1

Interventions

Fulvestrant 3trastuzumab deruxtecan 2Letrozole 2Injections 2AZD9833 2toripalimab 1ribociclib 1palbociclib 1exemestane 1abemaciclib 1Ritonavir 1Paclitaxel 1Lead 1Itraconazole 1Goserelin 1Anastrozole 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Cancer × toripalimab × 30 days × Clear all
NCT07602907 2026-05-22

Metronomic Oral Paclitaxel Monotherapy and Combined Immunotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose Exploration and Expansion Trial

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
44 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡